Neuland Laboratories Limited has informed the Exchange regarding Demise of Dr. Christopher M Cimarusti, Non- Executive Director of the company on February 28, 2026.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neuland Laboratories has informed the stock exchanges about the passing away of Dr. Christopher M Cimarusti, a Non-Executive Non-Independent Director, on February 28, 2026. Dr. Cimarusti had been associated with the company's board since 2009 and made notable contributions to the R&D function during his tenure. The disclosure has been made under SEBI Listing Regulations, listing his DIN (02872948), the reason (demise), and the date of cessation. The company has expressed deep sorrow and condolences to his family. No replacement appointment details have been disclosed in this filing.
The loss of a long-serving board member with deep R&D expertise is a governance event that may be viewed as mildly negative by the market, but it is unlikely to materially affect the stock price. Investors should watch for a future announcement regarding the appointment of a new director to fill the vacancy.